tetano
Editor, Senior Moderator
Cell
. 2021 Feb 9;S0092-8674(21)00160-4.
doi: 10.1016/j.cell.2021.02.010. Online ahead of print.
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection
Elizabeth M Anderson[SUP] 1 [/SUP], Eileen C Goodwin[SUP] 1 [/SUP], Anurag Verma[SUP] 2 [/SUP], Claudia P Arevalo[SUP] 1 [/SUP], Marcus J Bolton[SUP] 1 [/SUP], Madison E Weirick[SUP] 1 [/SUP], Sigrid Gouma[SUP] 1 [/SUP], Christopher M McAllister[SUP] 1 [/SUP], Shannon R Christensen[SUP] 1 [/SUP], JoEllen Weaver[SUP] 2 [/SUP], Philip Hicks[SUP] 3 [/SUP], Tomaz B Manzoni[SUP] 1 [/SUP], Oluwatosin Oniyide[SUP] 4 [/SUP], Holly Ramage[SUP] 5 [/SUP], Divij Mathew[SUP] 6 [/SUP], Amy E Baxter[SUP] 6 [/SUP], Derek A Oldridge[SUP] 6 [/SUP], Allison R Greenplate[SUP] 6 [/SUP], Jennifer E Wu[SUP] 7 [/SUP], C?cile Alanio[SUP] 7 [/SUP], Kurt D'Andrea[SUP] 6 [/SUP], Oliva Kuthuru[SUP] 6 [/SUP], Jeanette Dougherty[SUP] 6 [/SUP], Ajinkya Pattekar[SUP] 6 [/SUP], Justin Kim[SUP] 6 [/SUP], Nicholas Han[SUP] 6 [/SUP], Sokratis A Apostolidis[SUP] 6 [/SUP], Alex C Huang[SUP] 6 [/SUP], Laura A Vella[SUP] 8 [/SUP], Leticia Kuri-Cervantes[SUP] 1 [/SUP], M Betina Pampena[SUP] 1 [/SUP], UPenn COVID Processing Unit; Michael R Betts[SUP] 1 [/SUP], E John Wherry[SUP] 7 [/SUP], Nuala J Meyer[SUP] 4 [/SUP], Sara Cherry[SUP] 5 [/SUP], Paul Bates[SUP] 9 [/SUP], Daniel J Rader[SUP] 2 [/SUP], Scott E Hensley[SUP] 10 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread within the human population. Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the coronavirus disease 2019 (COVID-19) pandemic. Here, we quantified levels of SARS-CoV-2-reactive antibodies and hCoV-reactive antibodies in serum samples collected from 431 humans before the COVID-19 pandemic. We then quantified pre-pandemic antibody levels in serum from a separate cohort of 251 individuals who became PCR-confirmed infected with SARS-CoV-2. Finally, we longitudinally measured hCoV and SARS-CoV-2 antibodies in the serum of hospitalized COVID-19 patients. Our studies indicate that most individuals possessed hCoV-reactive antibodies before the COVID-19 pandemic. We determined that ∼20% of these individuals possessed non-neutralizing antibodies that cross-reacted with SARS-CoV-2 spike and nucleocapsid proteins. These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but they were boosted upon SARS-CoV-2 infection.
Keywords: SARS-CoV-2; antibodies; coronavirus; pre-existing immunity.
. 2021 Feb 9;S0092-8674(21)00160-4.
doi: 10.1016/j.cell.2021.02.010. Online ahead of print.
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection
Elizabeth M Anderson[SUP] 1 [/SUP], Eileen C Goodwin[SUP] 1 [/SUP], Anurag Verma[SUP] 2 [/SUP], Claudia P Arevalo[SUP] 1 [/SUP], Marcus J Bolton[SUP] 1 [/SUP], Madison E Weirick[SUP] 1 [/SUP], Sigrid Gouma[SUP] 1 [/SUP], Christopher M McAllister[SUP] 1 [/SUP], Shannon R Christensen[SUP] 1 [/SUP], JoEllen Weaver[SUP] 2 [/SUP], Philip Hicks[SUP] 3 [/SUP], Tomaz B Manzoni[SUP] 1 [/SUP], Oluwatosin Oniyide[SUP] 4 [/SUP], Holly Ramage[SUP] 5 [/SUP], Divij Mathew[SUP] 6 [/SUP], Amy E Baxter[SUP] 6 [/SUP], Derek A Oldridge[SUP] 6 [/SUP], Allison R Greenplate[SUP] 6 [/SUP], Jennifer E Wu[SUP] 7 [/SUP], C?cile Alanio[SUP] 7 [/SUP], Kurt D'Andrea[SUP] 6 [/SUP], Oliva Kuthuru[SUP] 6 [/SUP], Jeanette Dougherty[SUP] 6 [/SUP], Ajinkya Pattekar[SUP] 6 [/SUP], Justin Kim[SUP] 6 [/SUP], Nicholas Han[SUP] 6 [/SUP], Sokratis A Apostolidis[SUP] 6 [/SUP], Alex C Huang[SUP] 6 [/SUP], Laura A Vella[SUP] 8 [/SUP], Leticia Kuri-Cervantes[SUP] 1 [/SUP], M Betina Pampena[SUP] 1 [/SUP], UPenn COVID Processing Unit; Michael R Betts[SUP] 1 [/SUP], E John Wherry[SUP] 7 [/SUP], Nuala J Meyer[SUP] 4 [/SUP], Sara Cherry[SUP] 5 [/SUP], Paul Bates[SUP] 9 [/SUP], Daniel J Rader[SUP] 2 [/SUP], Scott E Hensley[SUP] 10 [/SUP]
Affiliations
- PMID: 33631096
- DOI: 10.1016/j.cell.2021.02.010
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread within the human population. Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the coronavirus disease 2019 (COVID-19) pandemic. Here, we quantified levels of SARS-CoV-2-reactive antibodies and hCoV-reactive antibodies in serum samples collected from 431 humans before the COVID-19 pandemic. We then quantified pre-pandemic antibody levels in serum from a separate cohort of 251 individuals who became PCR-confirmed infected with SARS-CoV-2. Finally, we longitudinally measured hCoV and SARS-CoV-2 antibodies in the serum of hospitalized COVID-19 patients. Our studies indicate that most individuals possessed hCoV-reactive antibodies before the COVID-19 pandemic. We determined that ∼20% of these individuals possessed non-neutralizing antibodies that cross-reacted with SARS-CoV-2 spike and nucleocapsid proteins. These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but they were boosted upon SARS-CoV-2 infection.
Keywords: SARS-CoV-2; antibodies; coronavirus; pre-existing immunity.